

This summary report outlines Aeris Active's superior performance as recorded from a range of internationally recognised test methods to demonstrate efficacy. Original test reports may be provided as required in line with requisite confidentiality agreements and approvals.

Formulation owner: Novapharm Research (Australia) Pty Ltd - 3-11 Primrose Avenue, Rosebery, NSW 2018
Licensee: Aeris Environmental Ltd.
Product identifier: PROD-23 and PROD-61



Category	Authority	Report Identifier	Performance Notes
EN 1276 Bactericidal: (Staphylococcus aureus Escherichia coli Pseudomonas aeruginosa Enterococcus hirae)	APEX BIOSOLUTIONS	EN 1276 Report Date: 06/17/2020	Passes EN 1276
EN 13727 Bactericidal: (Staphylococcus aureus Escherichia coli K12 Pseudomonas aeruginosa Enterococcus hirae)	APEX BIOSOLUTIONS	EN13727 Report Date: 06/17/2020	Passes EN 13727
EN 1650 Fungicidal: (Candida albicans Aspergillus brasiliensis)	APEX BIOSOLUTIONS	EN 1650 Report Date: 06/17/2020	Passes EN 1650
EN 13624 Fungicidal: (Candida albicans Aspergillus brasiliensis)	APEX BIOSOLUTIONS	EN 13624 Report Date: 06/17/2020	Passes EN 13624
EN 13697 Bactericidal and Fungicidal (Surfaces): (Staphylococcus aureus Escherichia coli Pseudomonas aeruginosa Enterococcus hirae Candida albicans Aspergillus brasiliensis)	APEX BIOSOLUTIONS	EN 13697 Report Date: 06/17/2020	Passes EN 13697
EN 14476 : A2 Virucidal: (Adenovirus, Norovirus and Polio- virus Coronavirus and Influenza virus H1N1)	APEX BIOSOLUTIONS	EN 14476:A2 Report Date: 06/17/2020	Passes EN 14476:A2
EN 16777 Virucidal (Surfaces): (Adenovirus and Norovirus)	APEX BIOSOLUTIONS	EN 16777 Report Date: 06/17/2020	Passes EN 16777
Adapted Protocol + EN 16777 Protocol Virucidal (Residual Effect During 7 Days): Norovirus Coronavirus and Influenza virus H1N1	APEX BIOSOLUTIONS	Adapted Protocol + EN 16777 Protocol Report Date: 06/17/2020	Passes residual effect against Norovi- rus, coronavirus and influenza virus H1N1 upto 7 days
Adapted Protocol + EN 16777 Protocol Virucidal (200 touches): Norovirus Coronavirus and Influenza virus H1N1	APEX BIOSOLUTIONS	Adapted Protocol + EN 16777 Protocol Report Date: 06/17/2020	Passes residual effect against Norovirus, coronavirus and influenza virus H1N1 after 200 touches